Acasti Pharma Inc Stock (APO.V)

Company description

Acasti Pharma Inc logo Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company’s product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Acasti is the producer of anti-dyslipidemic prescription drugs (CaPre), medical foods (Onemia) and over-the-counter (OTC) products (Vectos). During the fiscal year ended February 28, 2011 (fiscal 2011), the Company has completed the development and launched medical food, Onemia.

People involved

Fullname Position
Jerald Wenker Chairman of the Board
Andre Godin Interim President and Chief Executive Officer
Pierre Lemieux Chief Operating Officer
Harlan Waksal Executive Executive Vice President - Business and Scientific Affairs, Director
Tina Sampalis Chief Global Strategy Officer